Archive

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

A chemotherapy-free ponatinib-blinatumomab frontline regimen may replace imatinib plus intensive chemo in adult Ph-positive ALL, sparing patients transplant-era toxicity.

Oncology · NEJM · 15 Oct

Reframing cancer therapy through tumor plasticity.

Explains why tumours regress then relapse off targeted therapy: drug-tolerant states are reversible, so rechallenge or plasticity-directed combinations may work where dose escalation fails.

Oncology · Nature cancer · 14 Oct

Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial.

PSA <0.2 ng/ml at 12 months was 73% (95% CI 56-86%) with the combination versus 64.7% (95% CI 38-86%) with enzalutamide alone; grade ≥3 adverse events were 68% versus 35%, mainly anemia (41%).

Oncology · Nature Medicine · 14 Oct

Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial.

Nine of 12 evaluable Cohort B patients were vaccinated (75%, 90% CI 47-93%) and 1 of 9 Cohort A patients (11%, 90% CI 0.6-43%). No unexpected safety signals; no discontinuations for toxicity.

Oncology · Nature Medicine · 14 Oct

The Survival Gap: Why India’s Breast Cancer Survival Trails the World

Late presentation and patchy screening drive India's below-median breast cancer survival, so opportunistic palpation and prompt referral in your clinic still outperform any new drug.

Oncology · ETHealthworld · 12 Oct

A health-system-scale, episode-resolved multimodal atlas of cancer cachexia.

Cachectic episodes clustered near disease progression and were associated with inferior outcomes in nearly all cancer types; a multivariate model predicted impending cachectic weight loss in lung, colorectal and prostate cancer.

Oncology · Nature Medicine · 12 Oct

A modular framework for antibody-drug conjugate biomarkers.

No primary outcome or effect size. Authors argue response cannot be predicted by target expression alone; propose modules covering antigen abundance, trafficking, linker cleavage, payload susceptibility and toxicity.

Oncology · Nature reviews. Clinical oncology · 9 Oct

STAT+: AI for breast cancer risk prediction goes DTC, regulatory cloud over Utah sandbox, and AI psychosis

A direct-to-patient breast cancer risk algorithm bypasses your clinic, so patients may arrive with risk scores you did not order and cannot yet verify.

Oncology · STAT News — Health Tech · 8 Oct

STAT+: Why this startup is taking its AI to predict breast cancer risk directly to patients

A direct-to-patient AI risk tool may bring women to your clinic already worried about a calculated breast cancer risk you did not order or validate.

Oncology · STAT News — Health Tech · 8 Oct

Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum.

Reframes HER2-positive disease as curable early and long-surviving metastatic, so you can de-escalate therapy in low-risk patients without losing outcomes.

Oncology · Nature reviews. Clinical oncology · 8 Oct

Advances in Systemic Treatment of Breast Cancer.

No primary outcome or effect size reported. Describes trastuzumab deruxtecan improving outcomes in HER2-positive disease and checkpoint inhibitors improving outcomes in metastatic and early triple-negative disease.

Oncology · NEJM · 8 Oct

Exercise therapy in cancer prevention and treatment.

No primary result reported. The review synthesises existing evidence on exercise, host macroenvironment, tumour microenvironment and interaction with conventional cancer therapies.

Oncology · Nature reviews. Clinical oncology · 7 Oct

Hospital pricing part of wider value chain: Max MD

State scrutiny of consumable markups and in-hospital pharmacy pricing could change what your patients pay for cancer drugs and supplies.

Oncology · ETHealthworld · 6 Oct

Exploring the immunological effects of antibody-drug conjugates.

ADCs also reshape antitumour immunity, which may explain their activity in low-antigen tumours and inform how you sequence them with checkpoint inhibitors.

Oncology · Nature reviews. Clinical oncology · 6 Oct

Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma.

In vivo CAR-T avoids leukapheresis and lymphodepletion, so if durable responses hold, your relapsed myeloma patients could be treated without apheresis logistics.

Oncology · Nature Medicine · 6 Oct

Intestinal epithelial GSK3β governs fumarate-dependent neutrophil reprogramming to promote colorectal cancer.

Identifies a GSK3β-fumarate axis driving pro-tumour neutrophils in colorectal cancer, suggesting a target to overcome immunotherapy resistance.

Oncology · Nature cancer · 6 Oct

Smoking Cessation Among Underserved Patients Referred for Lung Cancer Screening: A Randomized Clinical Trial.

If your screening programme must offer cessation support, this trial shows which of four strategies actually works in underserved patients.

Oncology · JAMA · 5 Oct

Proposed nuclear safety rules threaten to stall Novartis’ Pluvicto expansion

If enacted, tighter nuclear licensing could delay or block Lu-177 PSMA therapy access for your metastatic prostate cancer patients, especially outside high-volume centres.

Oncology · Fierce Healthcare · 2 Oct

Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).

Confirms 5-year survival gains with neoadjuvant ICIs in resectable stage IIIB-D melanoma, supporting this as standard practice over upfront surgery.

Oncology · Nature Medicine · 1 Oct

Giredestrant plus Everolimus in Advanced Breast Cancer.

In 207 ESR1-mutated patients, median PFS was 10.0 months with giredestrant-everolimus versus 5.5 months with standard therapy-everolimus (HR 0.38; 95% CI 0.27 to 0.54; P<0.001). Overall population: 8.8 versus 5.5 months (HR 0.56; 95% CI 0.44 to 0.71).

Oncology · NEJM · 1 Oct

Anaplastic Large Cell Lymphoma of the Brain Mimicking an Extra-Axial Frontal Tumor: A Case Report

A dural-based frontal mass that looks like meningioma can be T-cell lymphoma; biopsy rather than assuming benign histology avoids delayed diagnosis.

Oncology · Cureus · 1 Oct

Adrenocortical Carcinoma: A Case Report on the Diagnostic and Therapeutic Approach

Uncontrolled hypertension can be the presenting sign of adrenocortical carcinoma; this case shows the imaging and surgical workup, though adjuvant therapy remains unstandardised.

Oncology · Cureus · 30 Sept

Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial.

If adding IV VCN-01 to gemcitabine-nab-paclitaxel improves survival in metastatic PDAC, it would be the first oncolytic virus regimen to enter first-line practice.

Oncology · Nature Medicine · 30 Sept

Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type, With Rapid Systemic Progression in an Elderly Patient: A Case Report

Leg-type cutaneous DLBCL can disseminate within weeks, so biopsy leg nodules promptly and stage systemically rather than treating as indolent skin disease.

Oncology · Cureus · 30 Sept

Management of Patients Undergoing Chemotherapy in Conservative Dentistry

Before dental work in a patient on chemotherapy, check for mucositis, bleeding risk and xerostomia, and time invasive procedures to the post-nadir window.

Oncology · Cureus · 30 Sept

'This is carnage', says SC on markup of 10 times on cancer drugs by hospitals

If hospitals must let patients buy chemo drugs outside, your patients could pay a fraction of in-house prices — expect pressure to change dispensing practice.

Oncology · ETHealthworld · 29 Sept

Chronic Myeloid Leukemia Progressing to Early T-Cell Precursor Lymphoblastic Blast Phase Following Treatment Default: An Integrated Morphologic, Immunophenotypic, Cytogenetic, and Molecular Case Report

Treatment interruption in chronic-phase CML can drive rare T-cell lymphoblastic blast crisis, so reinforce adherence and re-biopsy any patient losing molecular response.

Oncology · Cureus · 29 Sept

Immune Background Profiles Across B-cell Lymphoproliferative Disorders

Background T- and NK-cell patterns on routine flow cytometry may help subtype B-CLPDs without extra testing, but this is descriptive data, not a validated diagnostic rule.

Oncology · Cureus · 29 Sept

Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial.

First-in-class WRN inhibitor shows early activity in MSI-high tumours that have exhausted standard options, though phase 1 dosing and toxicity data are still maturing.

Oncology · Nature Medicine · 29 Sept

Multiple Myeloma Presenting as a Pancoast-Like Tumor: A Diagnostic Challenge

An apical lung mass in a smoker is not always Pancoast carcinoma; myeloma can mimic it, so biopsy before committing to lung-cancer treatment.

Oncology · Cureus · 28 Sept

Microwave Ablation Versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Initial complete ablation was similar (28 studies, 6,036 participants; RR 1.01, 95% CI 1.00-1.02). MWA reduced local tumour progression (27 studies, 5,166 participants; RR 0.67, 95% CI 0.54-0.83), consistent in randomised trials (RR 0.55, 95% CI 0.40-0.76).

Oncology · Cureus · 28 Sept

Bone Marrow Aplasia Under Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Rare and Unpredictable Complication

Rare but severe cytopenias can appear months into imatinib or nilotinib, so check marrow, not just counts, when a stable CML patient drops.

Oncology · Cureus · 28 Sept

Immune Checkpoint Inhibitors and Hypothyroidism: An Emerging Public Health Challenge Identified Through a Systematic Review of ClinicalTrials.gov

Checkpoint-inhibitor hypothyroidism is often permanent, so baseline and serial TSH testing is needed to catch lifelong levothyroxine dependence early in survivors.

Oncology · Cureus · 28 Sept

Sorafenib-Induced Hand-Foot Skin Reaction in a Patient With Acute Myeloid Leukemia Following Haploidentical Stem Cell Transplantation: A Case Report

Painful symmetrical hyperkeratotic plantar plaques appeared approximately eight weeks after starting sorafenib, impairing daily activities; managed with topical keratolytic and corticosteroid therapy.

Oncology · Cureus · 25 Sept

Unraveling the lexicon of complex mutational phenomena in human cancers.

No new data; the review clarifies ambiguous definitions and proposed origins of these eight phenomena and notes their reported associations with mutational processes, drug resistance and clinical outcomes

Oncology · Nature cancer · 25 Sept

Antimicrobial Resistance of Bacteria Isolated From Patients With Cancer

Enterobacteriaceae were 73.1% of isolates; ESBL prevalence 22.6%. E. coli MDR 51.0%, K. pneumoniae XDR 32.2%, Acinetobacter possible PDR 14.3%. E. coli resistance rose for ciprofloxacin and ceftriaxone in 2021.

Oncology · Cureus · 25 Sept

Cigna Group, OpenAI team up to support patients with complex conditions

Insurer-led AI navigation for cancer patients may change who coordinates your patients' care between visits, and what they bring to clinic.

Oncology · Fierce Healthcare · 24 Sept

Confirmed Myocarditis-Myositis Overlap Without Myasthenia Gravis: Evaluating for Triple M Syndrome Following Combined Enfortumab Vedotin and Pembrolizumab Therapy

Endomyocardial biopsy confirmed focal moderate lymphocytic myocarditis; troponin I, creatine phosphokinase, lactate dehydrogenase and transaminases were markedly elevated; acetylcholine receptor binding and muscle-specific kinase antibodies were negative.

Oncology · Cureus · 24 Sept

Complete Response to First-Line Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Extra-axial Central Nervous System Metastases

Suggests T-DXd can be used first-line for HER2-positive extra-axial CNS metastases, where treatment options are limited and prognosis poor.

Oncology · Cureus · 24 Sept

Grail survives adcomm vote as it awaits FDA decision for cancer blood test

A positive FDA panel vote moves Galleri closer to approval as a multi-cancer screening blood test, though its earlier trial miss means sensitivity limits still matter for how you counsel patients.

Oncology · Fierce Biotech · 24 Sept